JAK2 and myeloproliferative neoplasm: However, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for MF since ruxolitinib does not eliminate the myeloproliferative neoplasm (MPN) clone, reduce JAK2 V617F allele burden, or regress bone marrow fibrosis in most patients.